key: cord-0737140-ym3w5de8 authors: Li, Jian; Zhou, Xuelan; Zhang, Yan; Zhong, Fanglin; Lin, Cheng; McCormick, Peter J.; Jiang, Feng; Luo, Jun; Zhou, Huan; Wang, Qisheng; Fu, Yang; Duan, Jingjing; Zhang, Jin title: Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode date: 2020-10-29 journal: Sci Bull (Beijing) DOI: 10.1016/j.scib.2020.10.018 sha: ee32f68e2cecd443f4079e23c0d2535c4f194fae doc_id: 737140 cord_uid: ym3w5de8 [Figure: see text] Almost everyone is susceptible to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus, which can cause many symptoms and even death among high-risk individuals [1, 2] . The main protease (M pro , also known as 3CL pro ) is a cysteine protease essential for producing infectious virions and thus, an attractive target for drug development. Up to now, many studies using either in silico ligand docking or drug discovery based on available structures have been performed to discover new M pro -inhibiting agents [3, 4] . However, most studies have used either peptidomimetics or covalent inhibitors for M pro , which may introduce non-specific reactions with host proteins. Here, we presented the structure of shikonin in a non-covalent binding configuration with M pro and compared it with covalent bonding structures in pursuit of novel scaffolds capable of inhibiting the main protease. As shown in Fig. 1 , the crystal structure of M pro in complex with shikonin ( Shi M pro ) is resolved at 2.45 Å ( Fig.1 and Table S1 online), and shikonin binds to only one of the protomers (i.e., protomer A) despite their overall structural similarity ( Fig. S1 online, Supplementary materials and methods online). Shi M pro shows the same overall fold as for the apo structure of M pro at pH 7.5 ( apo M pro ) [5] . The root mean square (RMS) difference of equivalent Cα positions between apo and Shi M pro is ~0.3 Å (Fig. 2a ). An overlay of the Shi M pro structure with the previously solved inhibitor-bound structures shows high spatial conservation ( Fig. 2a and Fig. S2 online) . The inhibitor binding pocket is surrounded by S1-S4 subsites, and shikonin forms multiple interactions with them (Fig. 2a) . First, shikonin forms a hydrogen bond network with the protease polar triad Cys145 and His164 located on the S1 subsite. Second, the aromatic head groups of shikonin form a π-π interaction with His41 on the S2 subsite. Third, the hydroxy and methyl group of the isohexenyl side chain of shikonin tail form H-bonding with Arg188 and Gln189 on the S3 subsite, respectively. Superimposing Shi M pro with other inhibitor-bound structures reveals a striking difference in the arrangement of the catalytic dyad His41-Cys145 and smaller, but substantial, differences in Phe140 and Glu166. First, in covalent-bonding structures, the inhibitor binds to the Sγ atom of Cys145, but in the current structure, the side chain of Cys145 adopts a different configuration to form a hydrogen bond with shikonin ( Fig. 2b and 2c) . Second, shikonin forms H-bonds with Arg188 and Gln189 in the S3 pocket ( Fig. 2c and 2d) . Third, the imidazole group of His41 points toward the binding pocket in covalent-bonding structures, but it flips outward in the current structure, opening a way for the entry of shikonin. Fourth, the distance between His41 Nε2 and Cys145 Sγ is 5.3 Å in Shi M pro structure, significantly longer than those observed in other M pro structures (Fig. 2b) [6] [7] [8] [9] . Fifth, the phenyl ring of Phe140 in Shi M pro moves outward to the solvent and no longer has π-π interaction with His163. Lastly, the side chain of Glu166 is flexible in Shi M pro structures but is well ordered in covalent inhibitor binding structures (Fig. 2b) . Glu166 is strictly conserved among all M pro and is critical for forming a hydrogen bond with peptidomimetic inhibitors and N terminal residues from the other protomer [9] . The conformational change of Glu166 in the current Shi M pro structure may explain how the non-covalent binding of shikonin can inhibit protease activity. Additionally, the apo M pro structure has two water molecules in the substratebinding site (Fig. S3a online) . Water 1 forms a hydrogen bond network involving Phe140, His163, and Glu166 located in the S1 pocket, stabilizing the oxyanion hole in the apo state structure [5] . Water 2 hydrogen-bonded with His41 and Cys145. However, these two water molecules are not observed in the Shi M pro structure, and the space for water 2 in the apo structure is now occupied by shikonin (Fig. S3b online) , suggesting water molecule displacement may be part of the inhibitor mechanism. Unlike Shi M pro , covalent and peptidomimetic inhibitors bind to the S1/S2/S4 site, carmofur binds to the S2 subsite, and baicalein binds the S1/S2 pocket (Fig. 2e ) [6] [7] [8] [9] [10] . Therefore, the Shi M pro structure highlights a new mode of binding, and may serve as an invaluable resource to improve the design of novel antiviral drugs. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia A novel coronavirus from patients with pneumonia in china Α-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment Antiviral drug discovery: Norovirus proteases and development of inhibitors Structure of sars-cov-2 main protease in the apo state Structure-based design of antiviral drug candidates targeting the sars-cov-2 main protease Structure of m(pro) from SARS-CoV-2 and discovery of its inhibitors Structural basis for the inhibition of sars-cov-2 main protease by antineoplastic drug carmofur Crystal structure of sars-cov-2 main protease provides a basis for design of improved α-ketoamide inhibitors Discovery of baicalin and baicalein as novel, natural product inhibitors of sars-cov-2 3cl protease CAS) with a Ph.D. degree and worked as a postdoctoral fellow at the Shanghai Institute of Materia Medica He has a broad interest in structural biology and functional characterization of G protein-coupled receptors and ion pump/channels. He mainly focuses on drug discovery and development for chronic kidney disease and infectious diseases Supplementary materials to this article can be found online. The authors declare that they have no conflict of interest.